авторефераты диссертаций БЕСПЛАТНАЯ БИБЛИОТЕКА РОССИИ

КОНФЕРЕНЦИИ, КНИГИ, ПОСОБИЯ, НАУЧНЫЕ ИЗДАНИЯ

<< ГЛАВНАЯ
АГРОИНЖЕНЕРИЯ
АСТРОНОМИЯ
БЕЗОПАСНОСТЬ
БИОЛОГИЯ
ЗЕМЛЯ
ИНФОРМАТИКА
ИСКУССТВОВЕДЕНИЕ
ИСТОРИЯ
КУЛЬТУРОЛОГИЯ
МАШИНОСТРОЕНИЕ
МЕДИЦИНА
МЕТАЛЛУРГИЯ
МЕХАНИКА
ПЕДАГОГИКА
ПОЛИТИКА
ПРИБОРОСТРОЕНИЕ
ПРОДОВОЛЬСТВИЕ
ПСИХОЛОГИЯ
РАДИОТЕХНИКА
СЕЛЬСКОЕ ХОЗЯЙСТВО
СОЦИОЛОГИЯ
СТРОИТЕЛЬСТВО
ТЕХНИЧЕСКИЕ НАУКИ
ТРАНСПОРТ
ФАРМАЦЕВТИКА
ФИЗИКА
ФИЗИОЛОГИЯ
ФИЛОЛОГИЯ
ФИЛОСОФИЯ
ХИМИЯ
ЭКОНОМИКА
ЭЛЕКТРОТЕХНИКА
ЭНЕРГЕТИКА
ЮРИСПРУДЕНЦИЯ
ЯЗЫКОЗНАНИЕ
РАЗНОЕ
КОНТАКТЫ


Pages:     | 1 |   ...   | 5 | 6 ||

«КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ Ассоциация ревматологов России Научное общество гастроэнтерологов России Российское межрегиональное ...»

-- [ Страница 7 ] --

37:121—2. Pharmacokinet 2001;

40(4):245—62.

713. Rubin P., Yee J.P., Ruoff G. Comparison of 726. Iohom G., Walsh M., Higgins G., Shorten G.

long-term safety of ketorolac tromethamine and Effect of perioperative administration of dexketo aspirin in the treatment of chronic pain. profen on opioid requirements and inflammatory Pharmacotherapy 1990;

10:106—10. response following elective hip arthroplasty. Br J 714. Long-term ketorolac use: an evidence - Anaesth 2002;

88(4):520—6.

based summary of safety and efficacy. Drug News 727. Leman P., Kapadia Y., Herington J.

Update 2003;

5. На сайте: www.wsib.on.ca. Randomised controlled trial of the onset of anal 715. De Abajo F.J. Ketorolac and gastrointestinal gesic efficacy of dexketoprofen and diclofenac in lower limb injury. Emerg Med J 2003;

20(6):511—3. cacy and tolerability of intramuscular dexketopro 728. Sanchez-Carpena J., Dominguez-Hervella fen versus diclofenac in the symptomatic treat F., Garcia I. et al. Comparison of intravenous ment of acute low back pain. Clin Drug Investig dexketoprofen and dipyrone in acute renal colic. 2007;

27(8):533—43.

Eur J Clin Pharmacol 2007;

63(8):751-60. 738. Balfour J., Fitton A., Barradell L.

729. Bagan J., Lopez Arranz J., Valencia E. et al. Lornoxicam. A review of its pharmacology and Clinical comparison of dexketoprofen trometamol therapeutic potential in the management of and dipyrone in postoperative dental pain. J Clin painful and inflammatory conditions. Drugs Pharmacol 1998;

38(12 suppl):55—64. 1996;

51(4):639—57.

730. McGurk M., Robinson P., Rajayogeswaran 739. Norholt S., Sindet-Pedersen S., Larsen U. et V. et al. Clinical comparison of dexketoprofen al. Pain control after dental surgery: a double trometamol, ketoprofen, and placebo in postoper- blind, randomised trial of lornoxicam versus mor ative dental pain. J Clin Pharmacol 1998;

38(12 phine. Pain 1996;

67(2—3):335—43.

suppl):46—54. 740. Inan N., Ozcan N., Takmaz S. et al. Efficacy 731. Jimenez-Martinez E., Gasco-Garcia C., of lornoxicam in postoperative analgesia after Arrieta-Blanco J. et al. Study of the analgesic effi- total knee replacement surgery. Agri cacy of Dexketoprofen Trometamol 25 mg. vs. 2007;

19(2):38—45.

Ibuprofen 600 mg. after their administration in 741. Papadima A., Lagoudianakis E., Antonakis P.

patients subjected to oral surgery. Med Oral et al. Parecoxib vs. lornoxicam in the treatment of 2004;

9(2):138—43. postoperative pain after laparoscopic cholecystec 732. Ezcurdia M., Cortejoso F., Lanzon R. et al. tomy: a prospective randomized placebo-con Comparison of the efficacy and tolerability of trolled trial. Eur J Anaesthesiol 2007;

24(2):154—8.

dexketoprofen and ketoprofen in the treatment of 742. Sapolya O., Karamanhoglu B., Memis D.

primary dysmenorrhea. J Clin Pharmacol Analgesic effects of lornoxicam after total abdom 1998;

38(12 suppl):65—73. inal hysterectomy. J Opioid Manag 733. Allais G., De Lorenzo C., Airola G. et al. 2007;

3(3):155—9.

Dexketoprofen trometamol in the treatment of 743. Sener M., Yilmazer C., Yilmaz I. et al.

acute migraine attack. Minerva Med 2000;

91(7— Efficacy of lornoxicam for acute postoperative 8):153—9. pain relief after septoplasty: a comparison with 734. Zippel H., Wagenitz A. Comparison of the diclofenac, ketoprofen, and dipyrone. J Clin efficacy and safety of intravenously administered Anesth 2008;

20(2):103—8.

dexketoprofen trometamol and ketoprofen in the 744. Rose P., Steinhauser C. Comparison of management of pain after orthopaedic surgery: A Lornoxicam and Rofecoxib in Patients with multicentre, double-blind, randomised, parallel- Activated Osteoarthritis (COLOR Study). Clin group clinical trial. Clin Drug Investig Drug Investig 2004;

24(4):227—36.

2006;

26(9):517—28. 745. Yakhno N., Guekht A., Skoromets A. et al.

735. Rodriguez M., Contreras D., Galvez R. et al. Analgesic efficacy and safety of lornoxicam quick Double-blind evaluation of short-term analgesic release formulation compared with diclofenac efficacy of orally administered dexketoprofen potassium: randomised, double-blind trial in trometamol and ketorolac in bone cancer pain. acute low back pain. Clin Drug Investig Pain 2003;

104(1—2):103—10. 2006;

26(5):267—77.

736. Hanna M., Elliott K., Stuart-Taylor M. et al. 746. Kidd B., Frenzel W. A multicenter, random Comparative study of analgesic efficacy and mor- ized, double blind study comparing lornoxicam phine-sparing effect of intramuscular dexketopro- with diclofenac in osteoarthritis. J Rheumatol fen trometamol with ketoprofen or placebo after 1996;

23(9):1605—11.

major orthopaedic surgery. Br J Clin Pharmacol 747. Лазебник Л.Б., Дроздов В.Н., Коломиец 2003;

5(2):126—33. Е.В. Сравнительная эффективность и безо 737. Zippel H., Wagenitz A. A multicentre, ran- пасность применения кетопрофена, лорнок domised, double-blind study comparing the effi- сикама, нимесулида и целекоксиба у больных остеоартрозом. РМЖ 2004;

12(14):844–7. 1995;

14(6):656—62.

748. Цурко В.В., Балабанова Р.М., Олюнин 761. Kornasoff D., Frerick H., Bowdler J., Ю.А. и др. Внутрисуставное введение лорнок- Montull E. Aceclofenac is a well-tolerated alter сикама: клинико-экспериментальное обосно- native to naproxen in the treatment of вание и оценка эффективности. Consilium osteoarthritis. Clin Rheumatol 1997;

16(1):32—8.

medicum 2006;

(7):23–9. 762. Perez Busquier M., Calero E., Rodriguez M.

749. Насонова В.А. Вольтарен (диклофенак et al. Comparison of aceclofenac with piroxicam натрия) в ревматологии в начале XXI века. На in the treatment of osteoarthritis. Clin Rheumatol сайте: www.rmj.ru. 1997;

16(2):154—9.

750. Имаметдинова Г.Р., Чичасова Н.В. Воль- 763. Martin-Mola E., Gijon-Banos J., Ansoleaga тарен в практике ревматолога. На сайте: J. Aceclofenac in comparison to ketoprofen in the www.rmj.ru. treatment of rheumatoid arthritis. Rheumatol Int 751. 30 лет доверия вольтарену. На сайте: 1995;

15(3):111—6.

www.paininfo.ru. 764. Lemmel E., Leeb B., De Bast J., Aslanidis S.

752. Singh G., Vadhavkar S., Mithal A., Patient and physician satisfaction with ace Triadafilopoulos G. Comparing Apples with clofenac: results of the European Observational Oranges: Choice of Comparator Non-Selective Cohort Study (experience with aceclofenac for NSAIDs Alters the Gastrointestinal Safety inflammatory pain in daily practice). Aceclofenac Advantages of Cox-2 Inhibitors in Clinical Trials is the treatment of choice for patients and physi of Arthritis Patients. ACR 2007;

737. cians in the management of inflammatory pain.

753. McGettigan P., Henry D. Cardiovascular risk Curr Med Res Opin 2002;

18(3):146—53.

and inhibition of cyclooxygenase. JAMA 765. Haskinsson E.C., Irani M., Murray F.

2006;

296:1633—44. A large prospective open-label, multi-centre 754. Legrand E. Aceclofenac in the management SAMM study, comparing the safety of aceclofenac of inflammatory pain. Exp. Opion Pharmacother with diclofenac in patients with rheumatic dis 2004;

5(6):1347—57. ease. Eur J Rheumatol Inflam 2000;

17:1—7.

755. Насонова В.А. Ацеклофенак (аэртал) в 766. Lanas A., Garcia-Rodriguez L., Arroyo M.

ревматологической практике. Тер aрх et al. Risk of upper gastrointestinal ulcer bleeding 2005;

77(5):87–90. associated with selective cyclo-oxygenase- 756. Dingle J. The effects of NSAID on the inhibitors, traditional non-aspirin non-steroidal matrix of human articular cartilages. Z anti-inflammatory drugs, aspirin and combina Rheumatol 1999;

58(3):125—9. tions. GUT 2006;

55(12):1731—8.

757. Presser Lima P., Fontanella V. Analgesic effi- 767. Гришаева Г.П., Балабанова Р.М. Опыт cacy of aceclofenac after surgical extraction of применения АЭРТАЛА (АЦЕКЛОФЕНАКА) impacted lower third molars. Int J Oral при лечении ревматических заболеваний.

Maxillofac Surg 2006;

35(6):518—21. Трудный пациент 2005;

2.

758. Dooley M., Spencer C., Dunn C. 768. Moore N. Forty years of ibuprofen use. Int J Aceclofenac: a reappraisal of its use in the man- Clin Pract (suppl) 2003;

(135):28—31.

agement of pain and rheumatic disease. Drugs 769. Zuurmond W. Pain treatment with NSAIDs, 2001;

61(9):1351—78. primary focus on ibuprofen. Clin Rheumatol 759. Batlle-Gualda E., Roman Ivorra J., 2001;

20(suppl)1:6—8.

Martin-Mola E. et al. Aceclofenac vs paracetamol 770. Kokki H. Nonsteroidal anti-inflammatory in the management of symptomatic osteoarthritis drugs for postoperative pain: a focus on children.

of the knee: a double-blind 6-week randomized Paediatr Drugs 2003;

5(2):103—23.

controlled trial. Osteoarthritis Cartilage 771. Rampal P., Moore N., Van Ganse E. et al.

2007;

15(8):900—8. Gastrointestinal tolerability of ibuprofen com 760. Ward D., Veys E., Bowdler J., Roma J. pared with paracetamol and aspirin at over-the Comparison of aceclofenac with diclofenac in the counter doses. J Int Med Res 2002;

30(3):301—8.

treatment of osteoarthritis. Clin Rheumatol 772. Strom B., Schinnar R., Bilker W. et al.

Gastrointestinal tract bleeding associated with regard to morning stiffness and pain on awaken naproxen sodium vs ibuprofen. Arch Intern Med ing. Curr Med Res Opin 1993;

13(3):127—32.

1997;

157(22):2626—31. 784. Arone S. Long term study of ketoprofen SR 773. Blot W., McLaughlin J. GI bleeding in rela- in elderly patients. Scand J Rheumatol tion to analgesic use. Digestion 1998;

59:207. (suppl)1989;

83:15—9.

774. Singh G. Gastrointestinal complications and 785. Le Loet X. Safety of ketoprofen in the elder over-the-counter nonsteroidal anti-inflammatory ly: a prospective study on 20 000 patients. Scand J drugs: a view from ARAMIS database. Am J Rheumatol (suppl)1989;

83:21—7.

Therapeutics 2000;

7:115—21. 786. Schattenkirchner M. Long-term safety of keto 775. Autret-Leca E., Bensouda-Grimaldi L., profen in an elderly population of arthritic patients.

Maurage C., Jonville-Bera A. Upper gastroin- Scand J Rheumatol (suppl)1991;

91:27—36.

testinal complications associated with NSAIDs in 787. Чичасова Н.В., Иммаметдинова Г.Р., Ка children. Therapie 2007;

62(2):173—6. ратеев А.Е. и др. Эффективность и безопас 776. Hawkey C., Svoboda P., Fiedorowicz- ность кетопрофена (кетонал) при ревматоид Fabrycy I. et al. Gastroduodenal safety and tolera- ном артрите (клинико-эндоскопическое ис bility of lumiracoxib compared with Ibuprofen следование) Науч-практич ревматол and celecoxib in patients with osteoarthritis. 2001;

1:47–52.

J Rheumatol 2004;

31(9):1804—10. 788. Гельфанд Б.Р., Кириенко П.А., Леванович 777. M ller P., Simon B. Effects of ibuprofen Д.А., Борзенко А.Г. Сравнительная оценка lysinate and acetylsalicylic acid on gastric and эффективности нестероидных противовоспа duodenal mucosa. Randomized single-blind лительных препаратов, применяемых для пос placebo-controlled endoscopic study in healthy леоперационного обезболивания. Вестн ин volunteers. Arzneimittelforschung тенс тер 2002;

4:83–8.

1994;

44(7):840—3. 789. Lanza F., Codispoti J., Nelson E. An endo 778. Rodriguez S., Olguin A., Miralles C., scopic comparison of gastroduodenal injury with Viladrich P. Characteristics of meningitis caused over-the-counter doses of ketoprofen and aceta by Ibuprofen: report of 2 cases with recurrent minophen. Am J Gastroenterol episodes and review of the literature. Medicine 1998;

93(7):1051—4.

(Baltimore) 2006;

85(4):214—20. 790. Jerussi T., Caubet J., McCray J., Handley D.

779. Veys E. 20 years' experience with ketoprofen. Clinical endoscopic evaluation of the gastroduo Scand J Rheumatol Suppl 1991;

90(suppl)1—44. denal tolerance to (R)- ketoprofen, (R)- flur 780. Jokhio I., Siddiqui K., Waraich T. et al. biprofen, racemic ketoprofen, and paracetamol: a Study of efficacy and tolerance of ketoprofen and randomized, single-blind, placebo-controlled diclofenac sodium in the treatment of acute rheu- trial. J Clin Pharmacol 1998;

38(2 suppl):19—24.

matic and traumatic conditions. J Pak Med Assoc 791. Hart F., Boardman P. Indometacin: a new 1998;

48(12):373—6. non-steroidal antiinflammatory agent. BMJ 781. Осипова Н.А., Петрова В.В., Ермолаев 1963;

2(5363):965—70.

П.М., Береснев В.А. Нестероидные противо- 792. Lockie L. Tolerability and efficacy of long воспалительные препараты в лечении после- term daily administration of indomethacin for операционной боли у онкологических боль- moderate to severe chronic arthritic disorders.

ных. Фарматека 2006;

6:121. Clin Ther 1986;

8(4):398—405.

782. Mills S., Bloch M., Bruckner F. Double- 793. Ekstrand R., Alvan G., L'e Orme M. et al.

blind cross-over study of ketoprofen and ibupro- Double-blind dose-response study of fen in management of rheumatoid arthritis. Br indomethacin in rheumatoid arthritis. Eur J Clin Med J 1973;

4(5884):82—4. Pharmacol 1980;

17(6):437—42.

783. Uddenfeldt P., Leden I., Rubin B. A double- 794. Domljan Z., Durrigl T. Double-blind blind comparison of oral ketoprofen 'controlled crossover comparison of piroxicam and release' and indomethacin suppository in the indomethacin in rheumatoid arthritis. Eur J treatment of rheumatoid arthritis with special Rheumatol Inflamm 1983;

6(3):291—6.

795. Crowley B., Hamill J., Lyndon S. et al. лудка. Клин мед 1971;

1:3–9.

Controlled-release indomethacin and sustained- 808. Шостак Н.А., Рябкова А.А., Савельев release diclofenac sodium in the treatment of В.С., Малярова Л.Н. Желудочно-кишечное rheumatoid arthritis: a comparative controlled кровотечение как осложнение гастропатий, clinical trial. Curr Med Res Opin связанных с приемом нестероидных противо 1990;

12(3):143—50. воспалительных препаратов. Тер арх 796. Huskisson E. Four commonly prescribed 2003;

5:70–4.

non-steroidal anti-inflammatory drugs for 809. Kewitz H. Rare but serious risks associated rheumatoid arthritis. Eur J Rheumatol Inflamm with non-narcotic analgesics: clinical experience.

1991;

11(2):8—12. Med Toxicol 1986;

1(suppl)1:86—92.

797. Бочкова А.Г. Нестероидные противовос- 810. Willburger R., Mysler E., Derbot J. et al.

палительные препараты при анкилозирую- Lumiracoxib 400 mg once daily is comparable to щем спондилите. Consilium Medicum 2005;

7:2. indomethacin 50 mg three times daily for the 798. Бунчук Н.В. Анкилозирующий спонди- treatment of acute flares of gout. Rheumatology лит: Новые возможности и перспективы фар- (Oxford) 2007;

46(7):1126—32.

макотерапии. Фарматека 2006;

6:121. 811. Mastbergen S., Jansen N., Bijlsma J., 799. Calin A., Elswood J. A prospective nation- Lafeber F. Differential direct effects of cyclo-oxy wide cross-sectional study of NSAID usage in genase-1/2 inhibition on proteoglycan turnover of 1331 patients with ankylosing spondylitis. human osteoarthritic cartilage: an in vitro study.

J Rheumatol 1990;

17(6):801—3. Arthritis Res Ther 2006;

8(1):R2.

800. Zochling J., Bohl-B hler M., Baraliakos X. 812. Ding C. Do NSAIDs affect the progression of et al. Nonsteroidal anti-inflammatory drug use in osteoarthritis? Inflammation 2002;

26(3):139—42.

ankylosing spondylitis-a population-based survey. 813. Dingle J. The effects of NSAID on the Clin Rheumatol 2006;

25(6):794—800. matrix of human articular cartilages.

801. Khan M. A. A double blind comparison of Z Rheumatol 1999;

58(3):125—9.

diclofenac and indometacin in the treatment of 814. Rainsford K. Profile and mechanisms of gas ankylosing spondylitis. J Rheumatol trointestinal and other side effects of nonsteroidal 1987;

14:118—23. anti-inflammatory drugs (NSAIDs). Am J Med 802. Batlle-Gualda E., Figueroa M., Ivorra J., 1999;

107(6A):27—35.

Raber A. The efficacy and tolerability of ace- 815. Wiseman E., Chang Y., Lombardino J.

clofenac in the treatment of patients with anky- Piroxicam, a novel anti-inflammatory agent.

losing spondylitis: a multicenter controlled clini- Arzneimittelforschung 1976;

26(7):1300—3.

cal trial. Aceclofenac Indomethacin Study Group. 816. Tweddell E., Willcocks W. An evaluation of J Rheumatol 1996;

23(7):1200—6. piroxicam, a new non-steroidal anti-inflammato 803. Cronstein B., Terkeltaub R. The inflamma- ry agent. A multicentre trial. S Afr Med J tory process of gout and its treatment. Arthritis 1981;

59(25):915—6.

Res Ther 2006;

8(suppl 1):3. 817. Brogden R., Heel R., Speight T., Avery G.

804. Pittman J., Bross M. Diagnosis and manage- Piroxicam. A reappraisal of its pharmacology and ment of gout. Am Fam Physician 1999;

59:1799—806. therapeutic efficacy. Drugs 1984;

28(4):292—323.

805. Thompson M., Percy J. Further experience 818. Edwards J., Loke Y., Moore R., McQuay H.

with indomethacin in the treatment of rheumatic Single dose piroxicam for acute postoperative disorders. BMJ 1966;

5479:80—3. pain. Cochrane Database Syst Rev 806. Барскова В.Г., Якунина И.А. Противо- 2000;

(4):CD002762.

воспалительная терапия острого и хрониче- 819. SelНuk E., Gomel M., Apaydin S. et al. The ского подагрического артита Consilium postoperative analgesic efficacy and safety of Medicum 2005;

7:2. piroxicam (FDDF) and naproxen sodium. Int J 807. Василенко В.Х., Цодиков Г.В., Минуш- Clin Pharmacol Res 1998;

18(1):21—9.

кин О.Н. Влияние некоторых противоревма- 820. Englert R., Fontanesi G., MЯller P. et al.

тических средств на слизистую оболочку же- Piroxicam fast-dissolving dosage form in the treatment of patients with acute low back pain. 833. Martinez-Lavin M., Holman K., Smyth C., Clin Ther 1996;

18(5):843—52. Vaughan J. A comparison of naproxen, 821. Lightfoot R. Comparison of the efficacy and indomethacin and aspirin in osteoarthritis.

safety of etodolac and piroxicam in patients with J Rheumatol 1980;

7(5):711—6.

rheumatoid arthritis. Etodolac Study 326 834. Castles J., Moore T., Vaughan J. et al.

Rheumatoid Arthritis Investigators Group. Multicenter comparison of naproxen and J Rheumatol Suppl 1997;

47:10—6. indomethacin in rheumatoid arthritis. Arch Intern 822. Astorga Paulsen G., Baigun S., Galvao de Med 1978;

138(3):362—6.

Figueiredo J., Gomes de Freitas G. Efficacy and 835. Kajander A., Martio J. Diclofenac sodium tolerability comparison of etodolac and piroxicam (Voltaren) and naproxen in the treatment of in the treatment of patients with osteoarthritis of rheumatoid arthritis: a comparative double-blind the knee. Curr Med Res Opin 1991;

12(6):401—12. study. Scand J Rheumatol Suppl 1978;

22:57—62.

823. Atkinson M., Khanna V., Menard H. et al. A 836. Warner J., Weideman R., Kelly K. et al. The comparison of tenoxicam and piroxicam in the risk of acute myocardial infarction with etodolac treatment of rheumatoid arthritis. J Rheumatol is not increased compared to naproxen: a histori 1992;

19(4):538—42. cal cohort analysis of a generic COX-2 selective 824. Navani S., Raghu C., Jha R. et al. Phase IV inhibitor. J Cardiovasc Pharmacol Ther evaluation of piroxicam in acute and chronic 2008;

13(4):252—60.

painful inflammatory disorders: an Indian study. 837. Sibilia J., Deray G., Montalescot G. What do Int J Tissue React 1989;

11(1):47—51. we know about the cardiovascular toxicity of the 825. Муравьев Ю.В., Мамистова А.И., Сиги- NSAIDs? Presse Med 2006;

35(suppl 1):11—23.

дин Я.А. Пироксикам при лечении ревмато- 838. Farkouh M., Verheugt F., Ruland S. et al.

идного артрита. Тер арх 1988;

60 (4):128–30. A comparison of the blood pressure changes of 826. Runkel R., Chaplin M., Boost G. et al. lumiracoxib with those of ibuprofen and naprox Absorption, distribution, metabolism, and excre- en. J Clin Hypertens (Greenwich) tion of naproxen in various laboratory animals 2008;

10(8):592—602.

and human subjects. J Pharm Sci 839. Brook R., Kramer M., Blaxall B., Bisognano J.

1972;

61(5):703—8. Nonsteroidal Anti-Inflammatory Drugs and 827. Blechman W., Willkens R., Boncaldo G. et Hypertension. J Clin Hypertens (Greenwich) al. Naproxen in osteoarthrosis. Double-blind 2000;

2(5):319—23.

crossover trial. Ann Rheum Dis 1978;

37(1):80—4. 840. Gislason G., Rasmussen J., Abildstrom S. et 828. Bowers D., Dyer H., Fosdick W. et al. al. Increased mortality and cardiovascular mor Naproxen in rheumatoid arthritis. A controlled bidity associated with use of nonsteroidal anti trial. Ann Intern Med 1975;

83(4):470—5. inflammatory drugs in chronic heart failure. Arch 829. Aeidler H. Clinical results of a multicentral Intern Med 2009;

169(2):141—9.

double-blind examination of naproxen compared 841. Rahme E., Nedjar H. Risks and benefits of to indomethacin in chronic rheumatoid arthritis, COX-2 inhibitors vs non-selective NSAIDs: does ankylosing spondylitis, and osteoarthrosis. their cardiovascular risk exceed their gastrointesti Arzneimittelforschung 1975;

25(2A):315—8. nal benefit? A retrospective cohort study.

830. Melton J. 3rd, Lussier A., Ward J. et al. Rheumatology (Oxford) 2007;

46(3):4358.

Naproxen vs. aspirin in osteoarthritis of the hip 842. Rainsford K. Nimesulide — a multifactorial and knee. J Rheumatol 1978;

5(3):338—46. approach to inflammation and pain: scientific and 831. Bj rkenheim J., Helland J., Peltonen J. clinical consensus. Curr Med Res Opin A double-blind crossover evaluation of naproxen 2006;

22(6):1161—70.

and piroxicam in osteoarthritis of hip or knee. 843. Bianchi M., Broggini M. A randomized, J Int Med Res 1985;

13(5):263—9. double-blind, clinical trial comparing the efficacy 832. Clarke A. A Double-blind comparison of of nimesulide, celecoxib and rofecocxib in naproxen against indometacin in osteoarthrosis. osteoarthritis of the knee. Drag 2003;

63 (suppl Arzneimittelforschung 1975;

25(2A):302—4. 1):37—46.

844. Каратеев А.Е., Каратеев Д.Е., Лучихина 854. Насонов Е.Л. Эффективность и перено Е.Л. и др. Эффективность и безопасность мо- симость нестероидного противовоспалитель нотерапии высокими дозами НПВП при ран- ного препарата. Нимесулид: новые данные.

нем артрите. РМЖ 2006;

16:24–9. РМЖ 2001;

15:6–8.

845. L cker P., Pawlowski C., Friedrich I. et al. 855. Бадокин В.В. Применение нимесулида в Double-blind, randomised, multi-centre clinical ревматологической практике. Фарматека study evaluating the efficacy and tolerability of 2006;

6:32–6.

nimesulide in comparison with etodalac in 856. Балабанова Р.М., Белов Б.С., Чичасова patients suffering from osteoarthritis of the knee. Н.В. и др. Эффективность нимесулида при Eur J Rheumatol Inflamm 1994;

14(2):29—38. ревматоидном артрите. Фарматека 846. Huskisson E., Macciocchi A., Rahlfs V. et 2004;

7:55–8.

al. Nimesulide versus diclofenac in the treat-ment 857. Thompson J., Sharpe P., Kiani S., Owen of osteoarthritis of the hip or knee: an active con- Smith O. Effect of meloxicam on postoperative trolled equivalence study. Curr Ther Res pain after abdominal hysterectomy. Br J Anaesth 1999;

60:253—65. 2000;

84(2):151—4.

847. Kriegel W., Korff K., Ehrlich J. et al. 858. Akarsu T., Karaman S., Akercan F. et al.

Double-blind study comparing the long-term effi- Preemptive meloxicam for postoperative pain cacy of the COX-2 inhibitor nimesulide and relief after abdominal hysterectomy. Clin Exp naproxen in patients with osteoarthritis. Int J Clin Obstet Gynecol 2004;

31(2):133—6.

Pract 2001;

55(8):510—4. 859. Aoki T., Yamaguchi H., Naito H. et al.

848. Pilotto A., Franceschi M., Leandro G. et al. Premedication with cyclooxygenase-2 inhibitor The risk of upper gastrointestinal bleeding in eld- meloxicam reduced postoperative pain in patients erly users of aspirin and other non-steroidal anti- after oral surgery. Int J Oral Maxillofac Surg inflammatory drugs: the role of gastroprotective 2006;

35(7):613—7.

drugs. Aging Clin Exp Res 2003;

15(6):494—9. 860. Calvo A., Sakai V., Giglio F. et al. Analgesic 849. Menniti-Ippolito F., Maggini M., Raschetti and anti-inflammatory dose-response relationship R. et al. Ketorolac use in outpatients and gas- of 7,5 and 15 mg meloxicam after lower third trointestinal hospitalization: a comparision with molar removal: a double-blind, randomized, other non-steroidal anti-inflammatory drugs in crossover study. Int J Oral Maxillofac Surg Italy. Eur J Clin Pharmacol 1998;

54:393—7. 2007;

36(1):26—31.

850. Astarita C., Franzese A., Sproviero S. et al. 861. Kurukahvecioglu O., Karamercan A., Ege B.

The epidemiology of adverse reactions to nons- et al. Effect of meloxicam on postoperative pain teroidal anti-inflammatory drugs. Nimesulide is relief after inguinal hernia repair with local anaes tolerated by patients with adverse reactions to thesia. West Indian Med J 2007;

56(6):530—3.

NSAIDs and modulates in man the skin response 862. Anwari J., Anjum S., Al-Khunain S. Placebo to histamine and codeine. Recenti Prog Med controlled comparison of the opioid sparing effect 1992;

83(10):567—71. of meloxicam and diclofenac after abdominal hys 851. Asero R. Risk factors for acetaminophen and terectomy. Saudi Med J 2008;

29(3):379—83.

nimesulide intolerance in patients with NSAID- 863. Gilron I., Orr E., Tu D. et al. A randomized, induced skin disorders. Ann Allergy Asthma double-blind, controlled trial of perioperative Immunol 1999;

82(6):554—8. administration of gabapentin, meloxicam and their 852. Senna G., Passalacqua G., Dama A. et al. combination for spontaneous and movement Nimesulide and meloxicam are a safe alternative evoked pain after ambulatory laparoscopic chole drugs for patients intolerant to nonsteroidal anti- cystectomy. Anesth Analg 2009;

108(2):623—30.

inflammatory drugs. Eur Ann Allergy Clin 864. La Grenade C., Lee L., Weaver J. et al.

Immunol 2003;

35(10):393—6. Comparison of reporting of Stevens-Johnson 853. Каратеев А.Е., Барскова В.Г. Безопас- Syndrome and toxic epidermal necrosis in associ ность нимесулида: эмоции или взвешанная ation with selective COX-2 inhibitors. Drugs Saf оценка? Consilium medicum 2007;

9:60–4. 2005;

28(10):917—24.

865. Цветкова Е.С. Мовалис в терапии остео- логии. Науч-практич ревматол 2004;

1:39–42.

артроза. Науч-практич ревматол 2001;

1:67–71. 877. Цветкова Е.С., Алексеева Л.И., Балаба 866. Цветкова E.C. Оценка эффективности нова Р.М. и др. Эффективность и переноси применения мовалиса при остеоартрозе и мость целебрекса при остеоартрозе (данные ревматоидном артрите (данные многоцентро- российского исследования). Тер арх вого российского исследования). Науч-прак- 2001;

5:61–3.

тич ревматол 2005;

2:29–31. 878. Каратеев А.Е. Гастродуоденальная пере 867. Шостак Н.А., Аксенова А.В., Шеметов носимость целекоксиба (целебрекса) у боль Д.А., Аринина Е.Е. Опыт применения мова- ных остеоартрозом: эндоскопическая оценка.


лиса при синдроме болей в нижней части Тер арх 2001;

5:64–6.

спины (LBP). Тер арх 1999;

11:50–2. 879. Matsumoto A., Cavanaugh P. Etoricoxib.

868. Коган К.М., Золотарева Г.Д., Шмидт Drugs Today (Barc) 2004;

40(5):395—414.

Е.И. Опыт применения мовалиса у больных 880. Martina S., Vesta K., Ripley T. Etoricoxib: a остеоартритом в клиниках Москвы. Тер арх highly selective COX-2 inhibitor. Ann 1999;

11:52–4. Pharmacother 2005;

39(5):854—62.

869. Алексеев В.В., Алексеев А.В. Ранние и 881. Brooks P., Kubler P. Etoricoxib for arthritis отдаленные результаты лечения мелоксика- and pain management. Ther Clin Risk Manag мом болей в спине при остеоартрозе. 2006;

2(1):45—57.

Consilium medicum 2007;

9:28–33. 882. Schwartz J., Dallob A., Larson P. et al.

870. Каратеев А.Е. Использование целекокси- Comparative inhibitory activity of etoricoxib, cele ба в ревматологии, кардиологии, неврологии coxib, and diclofenac on COX-2 versus COX-1 in и онкологии. РМЖ 2007;

15,22(303):1660–8. healthy subjects. J Clin Pharmacol 871. Mastbergen S., Huisman A., Polak A. et al. 2008;

48(6):745—54.

Selective COX-2 inhibitor is beneficial for matrix 883. Malmstrom K., Sapre A., Couglin H. et al.

turnover of osteoartritic cartilage: a clinical study. Etoricoxib in acute pain associated with dental Ann Rheum Dis 2006;

65(suppl II):398. surgery: a randomized, double-blind, placebo 872. Rahme E., Bardou M., Dasgupta K. et al. and active comparator-controlled dose-ranging Hospitalization for gastrointestinal bleeding asso- study. Clin Ther 2004;

May;

26(5):667—79.

ciated with non-steroidal anti-inflammatory drugs 884. Liu W., Loo C., Tan H. et al. Comparison of among elderly patients using low-dose aspirin: a preemptive analgesia efficacy between etoricoxib retrospective cohort study. Rheumatology and rofecoxib in ambulatory gynecological sur (Oxford) 2007;

46(2):265—72. gery. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 873. Wang J., Mullins C., Mamdani M. et al. New 2004;

26(6):666—70.

diagnosis of hypertension among celecoxib and 885. Puura A., Puolakka P., Rorarius M. et al.

nonselective NSAID users: a population-based Etoricoxib pre-medication for post-operative pain cohort study. Ann Pharmacother after laparoscopic cholecystectomy. Acta 2007;

41(6):937—43. Anaesthesiol Scand 2006;

50(6):688—93.

874. Solomon S., Wittes J., Finn P. et al. 886. Rasmussen G., Malmstrom K., Bourne M.

Cardiovascular Risk of Celecoxib in 6 et al. Etoricoxib provides analgesic efficacy to Randomized Placebo-Controlled Trials. patients after knee or hip replacement surgery: a Circulation 2008;

117:2104—13. randomized, double-blind, placebo-controlled 875. Howes L. Selective COX-2 inhibitors, study. Anesth Analg 2005;

101(4):1104—11.

NSAIDs and cardiovascular events — is celecoxib 887. Chang D., Desjardins P., King T. et al. The the safest choice? Therapeutics and Clinical Risk analgesic efficacy of etoricoxib compared with Management 2007;

3(5):831—45. oxycodone/acetaminophen in an acute postoper 876. Чичасова Н.В., Имаметдинова Г.Р., Насо- ative pain model: a randomized, double-blind нов Е.Л. Целебрекс в лечении заболеваний clinical trial. Anesth Analg 2004;

99(3):807—15.

суставов у больных с факторами риска разви- 888. Malmstrom K., Kotey P., Cichanowitz N. et тия гастропатий и сердечно–сосудистой пато- al. Analgesic efficacy of etoricoxib in primary dys menorrhea: results of a randomized, controlled overall response: results pooled from two identical trial. Gynecol Obstet Invest 2003;

56(2):65—9. studies of etoricoxib in chronic low back pain.

889. Nor Azlin M., Maryasalwati I., Norzilawati Spine 2008;

1;

33(5):533—8.

M. et al. The efficacy of etoricoxib vs mefenamic 898. Bingham C. 3rd, Sebba A., Rubin B. et al.

acid in the treatment of primary dysmenorrhoea: Efficacy and safety of etoricoxib 30 mg and cele a randomised comparative trial. J Obstet coxib 200 mg in the treatment of osteoarthritis in Gynaecol 2008;

28(4):424—6. two identically designed, randomized, placebo 890. Rubin B., Burton R., Navarra S. et al. controlled, non-inferiority studies. Rheumatology Efficacy and safety profile of treatment with etori- (Oxford) 2007;

46(3):496—507.

coxib 120 mg once daily compared with 899. Hunt R., Harper S., Watson D. et al. The indomethacin 50 mg three times daily in acute gastrointestinal safety of the COX-2 selective gout: a randomized controlled trial. Arthritis inhibitor etoricoxib assessed by both endoscopy Rheum 2004;

50(2):598—606. and analysis of upper gastrointestinal events. Am J 891. Moore R., Derry S., McQuay H. Gastroenterol 2003;

98(8):1725—33.

Discontinuation rates in clinical trials in muscu- 900. Ramey D., Watson D., Yu C. et al. The inci loskeletal pain: meta-analysis from etoricoxib dence of upper gastrointestinal adverse events in clinical trial reports. Arthritis Res Ther clinical trials of etoricoxib vs. non-selective 2008;

10(3):R53. NSAIDs: an updated combined analysis. Curr 892. Krueger K., Lino L., Dore R. et al. Med Res Opin 2005;

21(5):715—22.

Gastrointestinal tolerability of etoricoxib in 901. Curtis S., Ko A., Bolognese J. et al. Pooled rheumatoid arthritis patients: results of the etori- analysis of thrombotic cardiovascular events in coxib vs diclofenac sodium gastrointestinal tolera- clinical trials of the COX-2 selective Inhibitor bility and effectiveness trial (EDGE-II). Ann etoricoxib. Curr Med Res Opin Rheum Dis 2008;


67(3):315—22. 2006;

22(12):236574.

893. Baraf H., Fuentealba C., Greenwald M. et 902. Quercia O., Emiliani F., Foschi F., Stefanini al. Gastrointestinal side effects of etoricoxib in G. Safety of etoricoxib in patients with reactions patients with osteoarthritis: results of the to NSAIDs. J Investig Allergol Clin Immunol Etoricoxib versus Diclofenac Sodium 2008;

18(3):163—7.

Gastrointestinal Tolerability and Effectiveness 903. Viola M., Quaratino D. Gaeta F. et al.

(EDGE) trial. J Rheumatol 2007;

34(2):408—20. Etoricoxib tolerability in patients with hypersensi 894. Van der Heijde D., Baraf H., Ramos-Remus tivity to nonsteroidal anti-inflammatory drugs. Int C. et al. Evaluation of the efficacy of etoricoxib in Arch Allergy Immunol 2007;

143(2):103—8.

ankylosing spondylitis: results of a fifty-two-week, 904. El Miedany Y., Youssef S., Ahmed I., El randomized, controlled study. Arthritis Rheum Gaafary M. Safety of etoricoxib, a specific 2005;

52(4):1205—15. cyclooxygenase-2 inhibitor, in asthmatic patients 895. Zerbini C., Ozturk Z., Grifka J. et al. with aspirin-exacerbated respiratory disease. Ann Efficacy of etoricoxib 60 mg/day and diclofenac Allergy Asthma Immunol 2006;

97(1):105—9.

150 mg/day in reduction of pain and disability in 905. Ostensen M., Khamashta M., Lockshin M.

patients with chronic low back pain: results of a 4- et al. Anti-inflammatory and immunosupressive week, multinational, randomized, double-blind drugs and reproduction. Arthritis Care Res study. Curr Med Res Opin 2005;

21(12):2037—49. 2006;

6:2009.

896. Birbara C., Puopolo A., Munoz D. et al. 906. Oѓstensen M., Skomsvoll J. Anti-inflamma Treatment of chronic low back pain with etori- tory pharmacotherapy during pregnancy. Expert coxib, a new cyclo-oxygenase-2 selective Opin Pharmacother 2004;

5(3):571—80.

inhibitor: improvement in pain and disability - a 907. Chan V. A mechanistic perspective on the randomized, placebo-controlled, 3-month trial. J specificity and extent of COX-2 inhibition in Pain 2003;

4(6):307—15. pregnancy. Drug Saf 2004;

27(7):421—6.

897. Sheldon E., Bird S., Smugar S. et al. 908. Ostensen M, Ostensen H. Safety of nons Correlation of measures of pain, function, and teroidal antiinflammatory drugs in pregnant patients with rheumatic disease. J Rheumatol 2004;

20(4):397—403.

1996;

23(6):1045—9. 922. Gardiner S., Doogue M., Zhang M., Begg E.

909. Burdan F., Belzek A. Current opinions on Quantification of infant exposure to celecoxib embryotoxic and teratogenic effects of ibuprofen. through breast milk. Br J Clin Pharmacol Pol Merkur Lekarski 2001;

11(63):266—70. 2006;

61(1):101—4.

910. Burdan F., Sykut J., Przybylski P. 923. Jacqz-Aigrain E., Serreau R., Boissinot C. et Developmental toxicity of naproxen. Pol Merkur al. Excretion of ketoprofen and nalbuphine in Lekarski 2007;

23(134):155—8. human milk during treatment of maternal pain 911. Bar-Oz B., Clementi M., Di Giantonio E. et after delivery. Ther Drug Monit 2007;

29(6):815—8.

al. Metamizol (dipyrone, optalgin) in pregnancy, 924. Wischnik A., Manth S., Lloyd J. et al. The is it safe? A prospective comparative study. Eur J excretion of ketorolac tromethamine into breast Obstet Gynecol Reprod Biol 2005;

119(2):176—9. milk after multiple oral dosing. Eur J Clin 912. Nielsen G., Sorensen H., Larsen H. et al. Pharmacol 1989;

36(5):521—4.

Risk of adverse birth outcome and miscarriage in 925. Lebedevs T., Wojnar-Horton R., Yapp P. et pregnant users of non-steroidal anti-inflammatory al. Excretion of indomethacin in breast milk. Br J drugs: population based observational study and Clin Pharmacol 1991;

32(6):751—4.

case-control study. BMJ 2001;

322:266—70. 926. Banta-Wright S. Minimizing infant exposure 913. Li D., Liu L., Odouli R. Exposure to non- to and risks from medications while breastfeeding.

steroidal anti-inflammatory drugs during preg- J Perinat Neonatal Nurs 1997;

11(2):71—84.

nancy and risk of miscarriage: population based 927. Harris R. Cyclooxygenase-2 (cox-2) and the cohort study. BMJ 2003;

327:368—73. inflammogenesis of cancer. Subcell Biochem 914. Keim S., Klebanoff M. Aspirin use and mis- 2007;

42:93—126.

carriage risk. Epidemiology 2006;

17(4):435—9. 928. Thun M., Henley S., Patrono C. Nonsteroidal 915. Kozer E., Costei A., Boskovic R. et al. anti-inflammatory drugs as anticancer agents:

Effects of aspirin consumption during pregnancy mechanistic, pharmacologic, and clinical issues.

on pregnancy outcomes: meta-analysis. Birth J Natl Cancer Inst 2002;

94:252—66.

Defects Res B Dev Reprod Toxicol 929. Gately S., Li W.W. Multiple roles of COX- 2003;

68(1):70—84. in tumor angiogenesis: a target for antiangiogenic 916. Alano M., Ngougmna E., Ostrea E., therapy. Semin Oncol 2004;

31 (suppl 7):2—11.

Konduri G. Analysis of nonsteroidal antiinflam- 930. Gr sch S., Maier T., Schiffmann S., matory drugs in meconium and its relation to per- Geisslinger G. Cyclooxygenase-2 (COX-2) sistent pulmonary hypertension of the newborn. Independent Anticarcinogenic Effects of Selective Pediatrics 2001;

107(3):519—23. COX-2 Inhibitors. J N Cancer Inst 917. Van Marter L., Leviton A., Allred E. et al. 2006;

98(11):736—47.

Persistent pulmonary hypertension of the new- 931. Renard J., Julemont F., de Leval X., Pirotte B.

born and smoking and aspirin and nonsteroidal The use of nimesulide and its analogues in cancer antiinflammatory drug consumption during preg- chemoprevention. Anticancer Agents Med Chem nancy. Pediatrics 1996;

97(5):658—63. 2006;

6(3):233—7.

918. Ito S., Lee A. Drug excretion into breast 932. Masferrer J., Leahy K., Koki A. et al.

milk-overview. Adv Drug Deliv Rev Antiangiogenic and Antitumor Activities of 2003;

55(5):617—27. Cyclooxygenase-2 Inhibitors. Cancer Research 919. Needs C., Brooks P. Antirheumatic medica- 2000;

60:1306—11.

tion during lactation. Br J Rheumatol 933. Subbaramaiah K., Du B., Chang M. et al.

1985;

24(3):291—7. Celecoxib inhibits prostate cancer growth: evi 920. Knoppert D., Stempak D., Baruchel S., dence of a cyclooxygenase-2-independent mecha Koren G. Celecoxib in human milk: a case report. nism. Clin Cancer Res 2005;

11(5):1999—2007.

Pharmacotherapy. 2003, 23(1):97—100. 934. Baron J. Epidemiology of non-steroidal anti 921. Hale T., McDonald R., Boger J. Transfer of inflammatory drugs and cancer. Prog Exp Tumor celecoxib into human milk. J Hum Lact Res 2003;

37:1—24.

935. Rostom A., Dube C., Lewin G. et al. 944. Arber N., Eagle C., Spicak J. et al.

Nonsteroidal anti-inflammatory drugs and Celecoxib for the prevention of colorectal ade cyclooxygenase-2 inhibitors for primary preven- nomatous polyps. N Engl J Med tion of colorectal cancer: a systematic review. 2006;

355(9):885—95.

Ann Intern Med 2007;

146:376—89. 945. Bertagnolli M., Eagle C., Zauber A. at al.

936. Burke C., Bauer W., Lasner B. Celecoxib for the prevention of sporadic col Chemopreventiom of colorectal cancer: slow, orectal adenomas. N Engl J Med steady progress. Clev Clin J Med 2003;

70:346—50. 2006;

355(9):873—84.

937. Gonzalez-Perez A., Garcia Rodriguez L., 946. Bresalier R.S., Sandler R.S., Quan H. et al.

Lopez-Ridaura R. Effects of non-steroidal anti - For the Adenomatous Polyp Prevention on Vioxx inflammatory drugs on cancer sites other than the (APPROVEe) Trial Investigators. Cardiovascular colon and rectum: a meta-analysis. BMC Cancer events associated with rofecoxib in a colorectal 2003;

31;

3(1):28. adenoma chemoprevention trial. New Engl J Med 938. Corley D., Kerlikowske K., Verma R., 2005;

352.

Buffler P. Protective association of 947. Pruthi R., Derksen J., Moore D. A pilot aspirin/NSAIDs and esophageal cancer: a sys- study of use of the cyclooxygenase-2 inhibitor tematic review and meta-analysis. celecoxib in recurrent prostate cancer after defini Gastroenterology 2003;

124(1):47—56. tive radiation therapy or radical prostatectomy.

939. Каратеев А.Е., Насонова В.А., Муравьев BJU Int 2004;

93(3):275—8.

Ю.В. Прием НПВП и риск развития злокаче- 948. Lundholm K., Daneryd P., K rner U. et al.

ственных опухолей верхних отделов желудоч- Evidence that long-term COX-treatment но-кишечного тракта. Тер арх 2001;

12:71–3. improves energy homeostasis and body composi 940. Roberts R., Jacobson D., Girman C. et al. tion in cancer patients with progressive cachexia.

A population-based of daily nonsteroidal anti- Int J Oncol 2004;

24(3):505—12.

inflammatory drug use and prostate cancer. Mayo 949. Lai V., George J., Richey L., Kim H. Results Clin Proc 2002;

77:219—25. of a pilot study of the effects of celecoxib on can 941. Khan K., Masferrer J., Woerner B. et al. cer cachexia in patients with cancer of the head, Enhanced cyclooxygenase-2 expression in spo- neck, and gastrointestinal tract. Head Neck 2007;

radic and familial adenomatous polyposis of the Jul 5 [Epub ahead of print].

human colon. Scand J Gastroenterol 950. Rodriguez M., Contreras D., Galvez R. et al.

2001;

36:865—9. Double-blind evaluation of short-term analgesic 942. Richard C., Berk T., Bapat B. et al. Sulindac efficacy of orally administered dexketoprofen for periampullary polyps in FAP patients. Int J trometamol and ketorolac in bone cancer pain.

Colorectal Dis 1997;

12:14—8. Pain 2003;

104(1—2):103—10.

943. Steinbach G., Lynch P., Phillips R. et al. The 951. McNicol E., Strassels S., Goudas L. et al.

effect of celecoxib, a cyclooxygenase-2 inhibitor, NSAIDS or paracetamol, alone or combined with in familial adenomatous polyposis. N Engl J Med opioids, for cancer pain. Cochrane Database Syst 2000;

342:1946—52. Rev 2005;

25(1):CD005180.

А.Е. Каратеев, Н.Н. Яхно, Л.Б. Лазебник, М.Л. Кукушкин, В.Н. Дроздов, В.А. Исаков, Е.Л. Насонов Применение нестероидных противовоспалительных препаратов.

Клинические рекомендации Редактор А.Г. Шегай Корректор Е.В. Кулачинская Макет и верстка А.В. Песков Подписано в печать 17.04. Формат 70х100/ печ.л. 5, Бумага мелованная Печать офсетная Тираж 3000 экз.

Заказ № Отпечатано в ЗАО «Д-Графикс»

ООО «ИМА-ПРЕСС»

Москва, ул. Житная, д. 14, стр. Заказ книг по телефону: 721 48

Pages:     | 1 |   ...   | 5 | 6 ||
 





 
© 2013 www.libed.ru - «Бесплатная библиотека научно-практических конференций»

Материалы этого сайта размещены для ознакомления, все права принадлежат их авторам.
Если Вы не согласны с тем, что Ваш материал размещён на этом сайте, пожалуйста, напишите нам, мы в течении 1-2 рабочих дней удалим его.